Pharmaceutical Blister Packaging Patents: Top Companies & Trends 2026
A data-backed view of pharmaceutical blister packaging patents: who leads filings, where filing activity concentrates by IPC class, and where the white space sits.
Filing growth = 2021 (8 records) → 2024 (4); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 328 records in scope (CR5), not the ranked leaders only.
What this dataset covers
Pharmaceutical blister packaging sits at the intersection of container engineering and drug protection: claims cover child-resistant and tamper-evident structures, oxygen and moisture barrier laminates, and the dispensing formats that carry unit-dose medication. This landscape draws on 328 published records filed or published between 2015 and the 2026 data cut-off, classified under packaging-specific IPC subclasses B65D and B65B with medicine-container class A61J layered on top.
Because publication lags filing by roughly 18 months, the most recent years in any filing trend understate real activity — 2025 and 2026 figures will keep rising as more records publish. The picture below treats 2024 as the last complete year for growth comparisons.
Filing trends and technology composition
Two views of the same 328-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend: a 2020 peak, then a pullback
Filings rose to a peak of 30 records in 2020, then fell — 2021's 8 filings dropped to 4 by 2024, a 50% decline over that three-year span. Read the 2025-2026 tail as incomplete rather than as a continuation of that decline; those years are still filling in as publications catch up with filing dates.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition: packaging structure dominates
B65D (containers & packaging) appears in 79.9% of the 328 records, far ahead of A61J (medicine containers) at 41.5% and B65B (packaging & wrapping) at 26.5%. B32B (layered products & laminates) at 22.3% marks the barrier-material side of the field; A61M, A61K, B65G and H05K each stay under 5%, pointing to thinner claim activity on fluid-delivery devices, formulation-specific packaging, conveying systems and embedded electronics.
Shares are the percentage of the 328 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Pharmaceutical Blister Packaging Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about pharmaceutical blister packaging patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaA representative filing and the most-cited records
EP2968729A1 — Packaging system for oxygen-sensitive medications
Described herein are pharmaceutical packaging systems which prevent oxidative degradation of oxygen-sensitive drugs, such systems including a primary packaging container with an oxygen permeable component, a secondary packaging with very low permeability to oxygen and an oxygen absorber.Filed by Fresenius Kabi Deutschland, published 2016-01-20.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5323907A | Child resistant package assembly for dispensing pharmaceutical medications | 2,067 |
| 2 | US8963714B2 | Tamper-evident packaging | 1,000 |
| 3 | US6411567B1 | Drug delivery management system | 297 |
| 4 | US20130126379A1 | Tamper-evident packaging | 216 |
| 5 | US5014851A | Package assembly for dispensing pharmaceutical medications and method of manufacturing the same | 197 |
| 6 | US5927500A | Pharmaceutical containment package | 157 |
| 7 | US4805377A | Method of packaging and sterilizing a pharmaceutical product | 116 |
| 8 | US5040353A | System for inspecting and recycling goods from defective packages on a blister packaging machine | 77 |
| 9 | US20030203141A1 | Blister package | 64 |
| 10 | US20040188312A1 | 024340 Childproof blister pack card | 62 |
Citation counts reflect a searched corpus and skew toward older filings; treat them as a signal of influence on later filers, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four figures worth sitting with before you decide where to file or who to watch.
The top of the field is dense, the rest is a long tail
Just five assignees hold 86 of the 328 records in scope — a little over a quarter of the field. The ranked leaders run 100 deep, but by the tenth position volume has dropped to 9 records, meaning most named entities in the ranking hold only a handful of filings each.
2020 was the high point; the last complete year shows a pullback
Filing volume peaked at 30 records in 2020. Comparing complete years, 2021's 8 filings fell to 4 by 2024 — a 50% decline. Whether that reflects a genuinely quieter field or just publication lag on newer filings will not be clear until 2025-2026 data fully publishes.
Packaging structure, not dosing mechanics, carries the claim density
B65D containers-and-packaging language appears in nearly four out of five records. A61J medicine-container claims sit in fewer than half. Device-adjacent classes — A61M body-fluid devices, A61K formulations, H05K electronics — each stay under 5%, suggesting connected or smart-packaging claims are still comparatively rare.
Filing is US- and Europe-anchored, with PCT as the main international route
The United States and the European Patent Office receive the largest share of filings, with WIPO PCT applications close behind as the primary vehicle for multi-jurisdiction protection. Canada, Australia and Germany trail as secondary but active national routes.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to pharmaceutical blister packaging patent landscape, with the prior art for and against each one.
Where to take this analysis
This landscape tells you where filing has concentrated. Turning that into a filing or freedom-to-operate decision means going deeper on specific claim language.
Map claim overlap against your own design
Run your current or planned blister packaging structure against the most-cited records here to see which claim elements already sit on dense prior art before you draft.
Explore in Patsnap Eureka →Track the under-5% device-adjacent classes
A61M, A61K and H05K show thin claim density today. If your work touches connected packaging or fluid-delivery integration, that thinness is either an opening or a sign the technology hasn't matured into filings yet.
Explore in Patsnap Eureka →Watch the 2025-2026 publication tail
Current-year figures are understated by publication lag. Re-check filing trend data in six to twelve months before concluding the field has genuinely slowed.
Explore in Patsnap Eureka →Common questions on pharmaceutical blister packaging patents
Filing in this space is concentrated but not dominated by a single company: the top five assignees together hold 26.2% of the 328 records in scope, with the leader alone accounting for 22 records. Beyond the top ten, whose combined share is 41.8% of records, the ranking thins out quickly into a long tail of assignees holding only a handful of filings each. This pattern — a dense top and a long tail — means a freedom-to-operate check needs to look well beyond the obvious names, since single-filing entrants can still hold a blocking claim in a narrow niche.
Filing peaked in 2020 at 30 records and has cooled since: comparing complete years, 2021's 8 filings dropped to 4 by 2024, a 50% decline over that span. That said, publication typically lags actual filing by around 18 months, so the 2025 and 2026 figures in any chart are still filling in and should not be read as confirming a continued slowdown. The safest read is that the field has cooled from its 2020 peak, with the true current trajectory not yet visible in published data.
The dominant classification is B65D (containers and packaging generally), present in 79.9% of the 328 records, reflecting the structural nature of most claims. A61J (containers for medicine) follows at 41.5%, and B65B (packaging and wrapping machinery/processes) at 26.5%. B32B (layered products and laminates) appears in 22.3% of records, capturing barrier-material and laminate claims for oxygen or moisture protection, while device-adjacent classes like A61M and H05K each stay under 5%, indicating that smart or connected packaging claims remain a small slice of the field.
EP2968729A1, filed by Fresenius Kabi Deutschland and published in 2016, describes a packaging system for oxygen-sensitive medications combining a primary container with an oxygen-permeable component, a low-oxygen-permeability secondary packaging layer, and an oxygen absorber between them. Anyone designing a similar three-layer barrier-and-absorber architecture for oxidation-sensitive drugs should check claim scope against this filing directly. It does not block packaging that relies on different barrier mechanisms, such as desiccant-based moisture control or single-layer high-barrier laminates without an absorber component.
The clearest under-claimed branches sit in the classes with the lowest record shares: A61M (devices for body fluids) at 4.6%, A61K (medicinal preparations) at 4.3%, B65G (conveying and material handling) at 2.7%, and H05K (printed circuits and assemblies) at 2.7% of the 328 records. These low shares suggest connected packaging, integrated dosing-and-delivery devices, and automated conveying or fill-line integration for blister formats are comparatively open relative to the dense structural claim space in B65D and A61J. Low filing density here reflects unclaimed space, not proven commercial viability, so validation work is still needed before relying on it.
Research Pharmaceutical Blister Packaging Patent Landscape in depth with Eureka
Go past this page: query the whole pharmaceutical blister packaging patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.